Guangdong Hybribio Biotech Co.,Ltd. is primarily involved in the creation, production, and distribution of nucleic acid molecular diagnostic solutions designed for healthcare facilities and laboratories. The company's comprehensive portfolio includes a diverse array of in-vitro diagnostic kits targeting infectious pathogens and genetic conditions, such as human papillomavirus (HPV), various sexually transmitted diseases, thalassemia, G6PD deficiency, hearing impairment susceptibility, phenylketonuria, hepatitis B virus, and early cancer detection. Additionally, Hybribio offers advanced real-time PCR kits, including those for a range of respiratory pathogens and specific genetic markers, alongside an assortment of sophisticated instruments like automated nucleic acid extraction systems, PCR analysis units, flow-through hybridization platforms, and fluorescent quantitative detection devices. Beyond product sales, the company provides essential after-sales technical assistance and specialized medical testing services encompassing genetic metabolic, infectious, molecular pathological, and tumor examinations. Their offerings serve critical national screening initiatives, clinical diagnostics, and research applications. With a robust presence across Asia Pacific, Southeast Asia, the Middle East, Europe, Africa, and South America, the company's diagnostic reagents are utilized in nearly 30 countries. Founded in 2003, Guangdong Hybribio Biotech Co.,Ltd. maintains its headquarters in Chaozhou, China. The company was listed on the GEM of Shenzhen Stock Exchange in April 2017. Recent activities include obtaining new invention patents for genomic analysis data processing and expanding its range of detection kits, such as a six-item respiratory pathogen nucleic acid detection kit in late 2025.